 Hepatitis
C Top News Articles
 |
| |
|
|
| Executive
Summary Now Available from Hepatitis B and C National
Expert Policy Forum |
HCV
Protease Inhibitor Telaprevir Demonstrates
Good Efficacy in Both Treatment-experienced and Treatment-naive
Patients
11-10-2009
|
Boosted
Narlaprevir plus Pegylated Interferon and Ribavirin
Leads to Rapid Viral Suppression in Genotype 1 Hepatitis
C Patients
11-10-2009
|
Nitazoxanide
plus Pegylated Interferon and Ribavirin Produces
Virological Response in Some Prior Non-responders with
Cirrhosis
11-10-2009
|
SPRINT-1
Study Shows Benefits of Response-guided Therapy with Experimental
HCV Protease Inhibitor Boceprevir
11-6-2009
|
Experimental
HCV Protease Inhibitor BI 201335
Demonstrates Promising Results in Combination with Pegylated
Interferon and Ribavirin
11-6-2009
|
Pegylated
Interferon Lambda Demonstrates Good Antiviral
Activity, May Cause Fewer Side Effects than Interferon
Alfa
11-3-2009
|
Liver
Transplant Outcomes Have Improved over Time
for Patients with and without Hepatitis C
11-3-2009
|
Rep.
Michael Honda Introduces Viral
Hepatitis and Liver Cancer Prevention and Control Act
of 2009
11-3-2009
|
AASLD
Liver Meeting Starts Today in Boston
10-30-2009
|
Individually
Tailored Duration of Hepatitis
C Treatment Does Not Improve Virological Response
10-30-2009
|
Researchers
Identify Markers for Aggressive
Liver Cancer
10-27-2009
|
HCV
Genotype 3 May Be Associated with More Rapid
Liver Fibrosis Progression in People with Chronic Hepatitis
C
10-27-2009
|
Coffee
Slows Progression of Liver Disease in Hepatitis C Patients
with Advanced Fibrosis or Cirrhosis
10-27-2009
|
Reducing
Ribavirin Dose Raises Relapse Risk for Chronic
Hepatitis C Patients, but Pegylated
Interferon May be Decreased after Week 12
10-20-2009
|
Idera
Pharmaceuticals Begins Phase 1 Trial of Toll-like
Receptor Agonist IMO-2125 for Chronic Hepatitis
C
10-13-2009
|
Blood
Cholesterol May Increase after Successful Hepatitis
C Treatment
10-09-2009 |
Pharmasset
Selects Investigational HCV Polymerase
Inhibitor PSI-879 for Preclinical Development
10-09-2009 |
Most
Patients with Low Baseline HBV Viral Load Can Safely Discontinue
Lamivudine (Epivir-HBV)
after Achieving Virological Suppression
10-09-2009 |
InterMune
and Roche Begin Trial of Ritonavir-boosted
ITMN-191 (RG7227) for Genotype 1 Chronic Hepatitis
C Patients
10-06-2009 |
IL-28
Gene Variations Predict Who Will Respond to
Interferon-based Treatment for Chronic Hepatitis C
10-06-2009 |
CDC
Releases New Hepatitis C Fact Sheet For Gay
and Bisexual Men That Recognizes Sexual Transmission Risk
9-25-2009 |
Hepatitis
C May Not Increase Mortality among Patients
Who Are Not Coinfected, Do Not Drink Heavily, and Do Not
Have Cirrhosis
9-25-2009 |
Symptomatic
Liver Disease
Is Common among Children and Adolescents with Hepatitis
C
9-22-2009 |
HCV
Re-infection
Is Common, Mainly Due to Injection Drug Use, among Canadian
Prisoners Treated for Hepatitis C
9-18-2009 |
HCV
Viral Load Decline during the First 24 Hours of Interferon-based
Therapy Predicts Long-term Outcomes in HIV-HCV
Coinfected Patients
9-18-2009 |
Experimental
Agent ATI-0810 Appears to Have Novel Mechanism
of Action against Hepatitis C Virus
9-15-2009 |
First
Participants Treated in Phase 2 Trial of Anadys HCV
Polymerase Inhibitor ANA598
9-15-2009 |
Medtronic
Begins Phase 2 Study of Interferon
Pump for Hepatitis C Patients
9-11-2009 |
Some
Prisoners Can Achieve Good Hepatitis
C Treatment Outcomes, but Response Rates May
Be Lower than those of Non-inmates
9-11-2009 |
FDA
Requires Updated Labeling for Interferon
Alpha Products Due to Recently Identified Safety
Issues
9-04-2009 |
Roche
and InterMune Begin Phase 2b Trial of HCV
Protease Inhibitor RG7227/ITMN-191
9-04-2009 |
MassBiologics
Announces Phase 1 Study of Monoclonal
Antibody Targeting HCV
9-04-2009 |
Genetic
Factors Influence Risk of Mother-to-child
Hepatitis C Virus Transmission
9-01-2009 |
Bone
Loss and Vitamin D Deficiency Are Common among
People with Liver Cirrhosis
9-01-2009 |
Genetic
Variation Helps Explain Differences in Response to Interferon-based
Therapy for Hepatitis C
8-21-2009 |
Experimental
Interferon-inducer ANA773
Demonstrates Antiviral Activity In Hepatitis C Treatment
Trial
8-21-2009 |
Advocates
Urge Consideration of Hepatitis
C Treatment for Active Injection Drug Users
8-14-2009 |
FDA
Changes Regulations for Expanded
Access to Investigational Drugs
8-14-2009 |
Diets
High in Protein and Cholesterol May Increase Risk of Liver
Cirrhosis and Cancer, while Carbohydrates May
Be Protective
8-7-2009 |
Pegasys
and PegIntron for Chronic Hepatitis C Perform
Similarly in IDEAL Study
7-28-2009 |
16th
International Symposium on Hepatitis
C Virus (HCV) and Related Viruses Set for October
3-7, 2009 in Nice on the French Riviera
7-21-2009 |
Increases
in ALT Late in the Course of Interferon-based
Therapy for Chronic Hepatitis C Predicts Relapse
7-17-2009 |
Hepatitis
C Raises Risk of Cardiovascular
Disease
7-10-2009 |
Interferon-based
Therapy Reduces or Reverses Liver Fibrosis
over the Long-term in Chronic Hepatitis C Patients
7-07-2009 |
Early
Bilirubin Elevation May Predict Severe Anemia during Interferon/ribavirin
Treatment for Chronic Hepatitis C
7-07-2009 |
FDA
Advisory Panel Urges "Black Box" Warning --
and Potential Ban -- on Prescription
Acetaminophen Combinations Due to Liver Toxicity
7-03-2009 |
Albumin
Interferon (Albuferon) and HCV Polymerase Inhibitor
PSI-7851 Advance in
Clinical Trials
7-03-2009 |
CDC
Researchers Release Latest Hepatitis
A, B, and C Statistics
6-23-2009 |
Detectable
HCV RNA at Week 8 Is Best Predictor of Relapse in Genotype
1 Hepatitis C Patients Treated with Pegylated
Interferon plus Ribavirin
6-23-2009 |
Effectiveness
of Pegylated Interferon plus
Ribavirin for Chronic Hepatitis C Patients
with HCV Genotypes 5 or 6
6-19-2009 |
Blood
Pressure Drug Losartan Associated with Liver
Fibrosis Regression in Small Study
6-19-2009 |
FDA
Alert Warns of Elevated Risk of Death in Liver Transplant
Recipients Who Switch to Rapamune
(Sirolimus)
6-16-2009 |
Many
People with Chronic Hepatitis B and C
Do Not Receive Appropriate Treatment
6-16-2009 |
Older
Genotype 3 Chronic Hepatitis C Patients Do Not Respond
as Well to Interferon-based Therapy
6-16-2009 |
Metabolic
Syndrome Is Associated with Increased Risk of Hepatocellular
Carcinoma in Chronic Hepatitis C Patients
6-9-2009 |
Strategies
for Managing Acetaminophen-related
Liver Disease and Acute Liver Failure
6-5-2009 |
Vitamin
B12 Levels May Help Predict Response to Interferon-based
Therapy for Chronic Hepatitis C
6-5-2009
|
HCV
Viral Load Decline at Day 2 of Interferon-based
Therapy Predicts Sustained Response, Explains
Poorer Outcomes in African-Americans
6-2-2009 |
Virco
and Siemens Diagnostics Sign Licensing Agreement Allowing
Virco to Develop New Platform for Use in Development of
New Therapies for Hepatitis C
6-2-2009 |
|
|
Report
Predicts Costly Epidemic of Advanced
Liver Disease among Baby Boomers with Chronic
Hepatitis C
5-29-2009 |
Reduced
Dose and Duration of PegIntron
plus Ribavirin Is Not as Effective as Standard
Therapy for Genotype 2 and 3 Hepatitis C Patients
5-29-2009 |
IDEAL
Study Shows that Greater Hemoglobin Decline during Treatment
with Pegylated Interferon plus
Ribavirin Is Associated with Better Response
5/22/09 |
On
World Hepatitis Day,
Ask "Am I Number 12?"
5/22/09 |
On
World Hepatitis Day, Ask "Am
I Number 12?"
5/19/09 |
Active
Injection Drug Users
and Those on Opiate Substitution Treatment Can Have Good
Hepatitis C Therapy Outcomes
5/19/09 |
Researchers
Report Promising Results from Studies of 3 Therapeutic
HCV Vaccines
5/19/09 |
FDA
Approves Dose Adjustments of PegIntron
and Rebetol for Certain Patients with Chronic
Hepatitis C
5/15/09 |
Hepatitis
C Treatment Is More Successful before Progression
to Advanced Liver Damage
5/15/09 |
Chronic
Hepatitis C Patients with Metabolic
Syndrome Are at Greater Risk of Death
5/08/09 |
Extended
72-week Treatment with Pegylated
Interferon plus Ribavirin Did Not Improve Outcomes
among Slow Responder Hepatitis C Patients
5/08/09 |
Early
Treatment of Acute Hepatitis
C with Pegylated Interferon Monotherapy Produces
Better Results than Delayed Combination Therapy
5/05/09 |
Pegylated
Interferon alfa-2b (PegIntron) Maintenance
Monotherapy May Reduce Esophageal Varices in Hepatitis
C Patients with Cirrhosis
5/05/09 |
Adding
Telaprevir Improves
Sustained Response to Pegylated
Interferon plus Ribavirin in Genotype 1 Chronic
Hepatitis C Patients (PROVE3)
5/01/09 |
Experimental
HCV Protease Inhibitor SCH 900518,
with or without Pegylated Interferon,
Appears Safe and Exhibits Good Antiviral Activity
5/01/09 |
FDA
Will Require Additional Warning Labels for Over-the-Counter
Painkillers, Including Tylenol, Aspirin and
Ibuprofen
5/01/09 |
Promising
Early Results from the First Clinical Trial of a Combination
Regimen of 2 Oral Antiviral Agents
for Chronic Hepatitis C
4/28/09 |
Adding
Boceprevir to PegIntron/Ribavirin
Significantly Improves Sustained Virological Response
in Chronic Hepatitis C Patients
4/28/09 |
Genes
that Regulate Interferon
Signaling May Help Explain Reduced Response to Hepatitis
C Therapy in African-American Patients
4/28/09 |
Re-treatment
of Chronic Hepatitis C Patients Who Do Not Respond to
Pegylated Interferon Alfa-2b
(PegIntron)
4/24/09 |
Liver
Cancer Drug Sorafenib (Nexavar)
May Also Alleviate Complications Due to Cirrhosis
4/24/09 |
Interferon-based
Therapy
for Hepatitis C Improves Fibrosis Even in Individuals
without Virological Response
4/21/09 |
Sustained
Response to Interferon-based
Therapy Reduces Risk of Diabetes in Hepatitis
C Patients
4/21/09
|
HCV
Vaccine Development
4/13/09 |
A
Small Proportion of Hepatitis C Patients Develop Liver
Cancer despite Sustained Response to Interferon-based
Therapy
4/13/09 |
Treatment
for HCV/HBV Coinfection
4/10/09 |
Pharmasset
Initiates First Clinical Trial of Second-generation HCV
Polymerase Inhibitor PSI-7851
4/10/09 |
Pegylated
Interferon alfa-2a (Pegasys) Relapse Rates
in Genotype 1 Chronic Hepatitis C Patients Depend on Weight-based
Ribavirin Dosage
4/07/09 |
Overview
of the Current Standard of Care for Treatment of Chronic
Hepatitis C
4/03/09 |
HCV
Reinfection and Superinfection Are Common among
Injection Drug Users
3/24/09
|
Review
Finds Albumin Interferon
for Chronic Hepatitis C Is Effective and Well-tolerated;
Phase 3 Results Show Non-inferiority to Pegylated
Interferon
3/20/2009 |
Long-term
Maintenance Interferon Did Not Prevent Hepatocellular
Carcinoma among Chronic Hepatitis C Patients in HALT-C
Study
3/17/2009 |
FDA
Approves New Indication for PegIntron
plus Ribavirin for Certain Patients Who Failed
Prior Hepatitis C Treatment
3/13/2009 |
U.S.
Liver Cancer Rate
Triples, but Survival Improves
3/13/2009 |
Vertex
Acquires VCH-222 and VCH-759,
Two Experimental Oral HCV Polymerase Inhibitors
3/09/2009 |
Merck
Will Buy Schering-Plough
for $41.1 Billion
3/09/2009 |
Open
Phase 3 Study of Eltrombopag
for Raising Platelet Levels in Patients with Chronic Liver
Disease and Thrombocytopenia
2/27/09 |
Phase
1 OPTIMA Trial Finds Controlled-release Nitazoxanide Improves
Response to Pegylated Interferon
plus Ribavirin
2/27/09 |
Abbott
and Enanta Announce First Clinical Trial of Oral HCV Protease
Inhibitor ABT-450
2/20/2009
|
iTherX
Pharmaceuticals Announces Phase 2a Proof-of-concept Trial
of First Hepatitis C Virus Entry
Inhibitor
2/13/2009
|
Cyclical
Treatment Interruption in Patients Taking Interferon-based
Therapy for Chronic Hepatitis C
2/10/2009
|
Hepatitis
C Virus May Persists at Low Levels after Sustained Response
to Treatment; Liver Cancer May Develop Years Later
2/06/2009
|
Extended
Pegylated Interferon plus Ribavirin Therapy Improves Sustained
Response Rate in Slow Responder Genotype 1b Hepatitis
C Patients
2/03/2009
|
Debiopharm
Begins Randomization of Participants in Phase 2b Trial
of Cyclophilin Inhibitor Debio 025 for Chronic Hepatitis
C
2/03/2009
|
| |
